心筋梗塞:治療薬開発パイプライン動向(2014年下半期)

◆英語タイトル:Myocardial Infarction - Pipeline Review, H2 2014
◆商品コード:GMDHC5240IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2014年7月15日
◆ページ数:316
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥228,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥684,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。



【レポートの概要】

Myocardial Infarction – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Myocardial Infarction – Pipeline Review, H2 2014’, provides an overview of the Myocardial Infarction’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Myocardial Infarction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Infarction and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myocardial Infarction
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Myocardial Infarction and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Myocardial Infarction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Myocardial Infarction pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Myocardial Infarction
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Myocardial Infarction pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Myocardial Infarction Overview 11
Therapeutics Development 12
Pipeline Products for Myocardial Infarction – Overview 12
Pipeline Products for Myocardial Infarction – Comparative Analysis 13
Myocardial Infarction – Therapeutics under Development by Companies 14
Myocardial Infarction – Therapeutics under Investigation by Universities/Institutes 19
Myocardial Infarction – Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Unknown Stage Products 24
Myocardial Infarction – Products under Development by Companies 25
Myocardial Infarction – Products under Investigation by Universities/Institutes 30
Myocardial Infarction – Companies Involved in Therapeutics Development 31
Sanofi 31
AstraZeneca PLC 32
Advanced Cell Technology, Inc. 33
Athersys, Inc. 34
GlaxoSmithKline plc 35
Merck & Co., Inc. 36
BioLineRx, Ltd. 37
FibroGen, Inc. 38
Laboratoires Pierre Fabre SA 39
Zydus Cadila Healthcare Limited 40
Hadasit Medical Research Services & Development Ltd 41
A. Menarini Industrie Farmaceutiche Riunite Srl 42
Bayer AG 43
Merck KGaA 44
Ligand Pharmaceuticals, Inc. 45
Lixte Biotechnology Holdings, Inc. 46
Mesoblast Limited 47
Compugen Ltd. 48
Cardio3 BioSciences SA 49
CSL Limited 50
NeoStem, Inc. 51
LG Life Sciences, Ltd. 52
Pluristem Therapeutics Inc. 53
Juventas Therapeutics, Inc. 54
Bharat Biotech International Limited 55
Omni Bio Pharmaceutical Inc. 56
Remedy Pharmaceuticals, Inc. 57
Fina Biotech 58
QUANTUM GENOMICS Corp. 59
Angion Biomedica Corp. 60
GliaMed, Inc. 61
TaiGen Biotechnology Co., Ltd. 62
Lacer, S.A. 63
ViroMed Co., Ltd. 64
Medestea Research & Production S.p.A. 65
Lee’s Pharmaceutical Holdings Limited 66
Genextra S.p.a. 67
Vicore Pharma AB 68
Cellmid Limited 69
Saneron CCEL Therapeutics, Inc. 70
Serodus ASA 71
Targazyme, Inc. 72
Aprogen, Inc. 73
Amarantus Bioscience Holdings, Inc. 74
APT Therapeutics, Inc. 75
DecImmune Therapeutics, Inc. 76
Inbiopro Solutions Pvt. Ltd. 77
Immune Pharmaceuticals, Inc. 78
CellProthera SAS 79
Recardio GmbH 80
BEAT BioTherapeutics Corp. 81
Myocardial Infarction – Therapeutics Assessment 82
Assessment by Monotherapy Products 82
Assessment by Combination Products 83
Assessment by Target 84
Assessment by Mechanism of Action 88
Assessment by Route of Administration 92
Assessment by Molecule Type 94
Drug Profiles 97
THR-100 – Drug Profile 97
amediplase – Drug Profile 99
ticagrelor – Drug Profile 100
rivaroxaban – Drug Profile 103
clopidogrel bisulfate – Drug Profile 107
Bone Marrow Derived Mononuclear Cells for Cardiovascular Diseases – Drug Profile 109
Stem Cell Therapy for Cardiovascular Diseases – Drug Profile 111
BB-3 – Drug Profile 113
CSL-112 – Drug Profile 115
CEP-41750 – Drug Profile 116
losmapimod – Drug Profile 118
MTP-131 – Drug Profile 120
BQ-123 – Drug Profile 122
RNS-60 – Drug Profile 124
AMR-001 – Drug Profile 126
LC-280126 – Drug Profile 128
Autologous Myoblasts – Drug Profile 130
REC-01 – Drug Profile 132
CAP-1002 – Drug Profile 133
ZK-001 – Drug Profile 134
Stem Cell Therapy for Cardiovascular Diseases – Drug Profile 136
CTX-101 – Drug Profile 138
Stempeucel-AMI – Drug Profile 139
Alpha-1 Antitrypsin – Drug Profile 140
MultiStem – Drug Profile 141
Stem Cell Based Cardiac Therapy – Drug Profile 144
burixafor – Drug Profile 145
CIGB-500 – Drug Profile 147
Gene Therapy for Acute Myocardial Infarction – Drug Profile 148
FG-4539 – Drug Profile 149
GM-1485 – Drug Profile 150
CM-1 – Drug Profile 152
BL-7060 – Drug Profile 154
CGEN-856 – Drug Profile 156
rusalatide acetate – Drug Profile 157
CGEN-857 – Drug Profile 160
Stem Cell Therapy for Cardiovascular Diseases – Drug Profile 161
LB-100 – Drug Profile 163
JVS-100 – Drug Profile 165
Stromal-Derived Factor 1 for Cardiovascular Diseases – Drug Profile 167
C3BSGQR-1 – Drug Profile 168
glyburide – Drug Profile 169
HYPER-IL-6 – Drug Profile 172
CMK-103 – Drug Profile 173
Stem Cell Therapy for Blood and Cardiovascular Diseases – Drug Profile 174
LA-8045 – Drug Profile 175
AMRS-001 – Drug Profile 176
C-21 – Drug Profile 177
IBPB-005ET – Drug Profile 179
AP-102 – Drug Profile 180
ANG-4011 – Drug Profile 181
EP-1013 – Drug Profile 182
AS-605240 – Drug Profile 183
ICG-001 – Drug Profile 185
Autologous CD34 Stem Cells – Drug Profile 186
Intramyocardial Cardiospheres – Drug Profile 187
APT-102 – Drug Profile 188
JI-38 – Drug Profile 190
A-HSP27 – Drug Profile 191
Drugs to Inhibit Myosin for Cardiovascular Disorders – Drug Profile 192
Small Molecules to Inhibit mPTP for Cardiovascular and Neurodegenerative Diseases – Drug Profile 193
p66Shc Protein Inhibitors for Myocardial Infarction – Drug Profile 194
Conjugated Monoclonal Antibody Targeting hMR for Myocardial Infarction – Drug Profile 195
Adipose Tissue Derived Stem Cells – Drug Profile 196
Fc-Alpha-1 Antitrypsin – Drug Profile 197
Monoclonal Antibody to Inhibit CD20 for Cardiovascular Disease – Drug Profile 198
Messenger RNA Therapeutics for Cardiometabolic Diseases and Renal diseases – Drug Profile 199
TZ-101 – Drug Profile 200
N2 Antibody For Myocardial Infarction – Drug Profile 202
BBR-12 – Drug Profile 203
SER-130 – Drug Profile 204
Drugs to Inhibit Sir2 Protein for Ischemic Stroke and Myocardial Infarction – Drug Profile 205
Cell Therapy for Myocardial Infarction – Drug Profile 206
Human Pericytes + ckit Cardiac Progenitor Cells – Drug Profile 207
NL-005 – Drug Profile 208
FcAAT-3 – Drug Profile 209
FcAAT-2 – Drug Profile 210
C3BSGQR-4 – Drug Profile 212
AVE-0991 – Drug Profile 213
Biglycan Therapy for Cardiovascular Diseases – Drug Profile 214
Small Molecules to Inhibit MMP for Myocardial Infarction – Drug Profile 216
Iron Oxide Nanoparticles – Drug Profile 217
VN-100 – Drug Profile 218
Small Molecules to Antagonize Adenosine A2B Receptor for Asthma and Myocardial Infarction – Drug Profile 219
Human Umbilical Cord Blood Cell Therapy for Neurological and Cardiovascular Diseases – Drug Profile 220
QGC-101 – Drug Profile 222
RNAi Oligonucleotide for Myocardial Infarction – Drug Profile 223
Biosimilar 3 for Rheumatoid Arthritis and Acute Myocardial Infarction – Drug Profile 224
Biosimilar 4 for Acute Myocardial Infarction and Infertility – Drug Profile 225
Small Molecules to Inhibit PARP for Immunology, Oncology, Cardiovascular and Metabolic Disorders – Drug Profile 226
Proteins for Cardiovascular and Infectious Disease – Drug Profile 227
Small Molecules to Inhibit TNF-a for Cardiovascular and CNS Disorders – Drug Profile 228
Small Molecules for Myocardial Infarction – Drug Profile 229
Ephrin A-1 – Drug Profile 230
VM-202 – Drug Profile 231
Myocardial Infarction – Recent Pipeline Updates 233
Myocardial Infarction – Dormant Projects 299
Myocardial Infarction – Discontinued Products 301
Myocardial Infarction – Product Development Milestones 302
Featured News & Press Releases 302
Appendix 309
Methodology 309
Coverage 309
Secondary Research 309
Primary Research 309
Expert Panel Validation 309
Contact Us 310
Disclaimer 310

List of Tables
Number of Products under Development for Myocardial Infarction, H2 2014 18
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H2 2014 19
Number of Products under Development by Companies, H2 2014 21
Number of Products under Development by Companies, H2 2014 (Contd..1) 22
Number of Products under Development by Companies, H2 2014 (Contd..2) 23
Number of Products under Development by Companies, H2 2014 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2014 26
Comparative Analysis by Late Stage Development, H2 2014 27
Comparative Analysis by Clinical Stage Development, H2 2014 28
Comparative Analysis by Early Stage Development, H2 2014 29
Comparative Analysis by Unknown Stage Development, H2 2014 30
Products under Development by Companies, H2 2014 31
Products under Development by Companies, H2 2014 (Contd..1) 32
Products under Development by Companies, H2 2014 (Contd..2) 33
Products under Development by Companies, H2 2014 (Contd..3) 34
Products under Development by Companies, H2 2014 (Contd..4) 35
Products under Investigation by Universities/Institutes, H2 2014 36
Myocardial Infarction - Pipeline by Sanofi, H2 2014 37
Myocardial Infarction - Pipeline by AstraZeneca PLC, H2 2014 38
Myocardial Infarction - Pipeline by Advanced Cell Technology, Inc., H2 2014 39
Myocardial Infarction - Pipeline by Athersys, Inc., H2 2014 40
Myocardial Infarction - Pipeline by GlaxoSmithKline plc, H2 2014 41
Myocardial Infarction - Pipeline by Merck & Co., Inc., H2 2014 42
Myocardial Infarction - Pipeline by BioLineRx, Ltd., H2 2014 43
Myocardial Infarction - Pipeline by FibroGen, Inc., H2 2014 44
Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H2 2014 45
Myocardial Infarction - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 46
Myocardial Infarction - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2014 47
Myocardial Infarction - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 48
Myocardial Infarction - Pipeline by Bayer AG, H2 2014 49
Myocardial Infarction - Pipeline by Merck KGaA, H2 2014 50
Myocardial Infarction - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 51
Myocardial Infarction - Pipeline by Lixte Biotechnology Holdings, Inc., H2 2014 52
Myocardial Infarction - Pipeline by Mesoblast Limited, H2 2014 53
Myocardial Infarction - Pipeline by Compugen Ltd., H2 2014 54
Myocardial Infarction - Pipeline by Cardio3 BioSciences SA, H2 2014 55
Myocardial Infarction - Pipeline by CSL Limited, H2 2014 56
Myocardial Infarction - Pipeline by NeoStem, Inc., H2 2014 57
Myocardial Infarction - Pipeline by LG Life Sciences, Ltd., H2 2014 58
Myocardial Infarction - Pipeline by Pluristem Therapeutics Inc., H2 2014 59
Myocardial Infarction - Pipeline by Juventas Therapeutics, Inc., H2 2014 60
Myocardial Infarction - Pipeline by Bharat Biotech International Limited, H2 2014 61
Myocardial Infarction - Pipeline by Omni Bio Pharmaceutical Inc., H2 2014 62
Myocardial Infarction - Pipeline by Remedy Pharmaceuticals, Inc., H2 2014 63
Myocardial Infarction - Pipeline by Fina Biotech, H2 2014 64
Myocardial Infarction - Pipeline by QUANTUM GENOMICS Corp., H2 2014 65
Myocardial Infarction - Pipeline by Angion Biomedica Corp., H2 2014 66
Myocardial Infarction - Pipeline by GliaMed, Inc., H2 2014 67
Myocardial Infarction - Pipeline by TaiGen Biotechnology Co., Ltd., H2 2014 68
Myocardial Infarction - Pipeline by Lacer, S.A., H2 2014 69
Myocardial Infarction - Pipeline by ViroMed Co., Ltd., H2 2014 70
Myocardial Infarction - Pipeline by Medestea Research & Production S.p.A., H2 2014 71
Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 72
Myocardial Infarction - Pipeline by Genextra S.p.a., H2 2014 73
Myocardial Infarction - Pipeline by Vicore Pharma AB, H2 2014 74
Myocardial Infarction - Pipeline by Cellmid Limited, H2 2014 75
Myocardial Infarction - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2014 76
Myocardial Infarction - Pipeline by Serodus ASA, H2 2014 77
Myocardial Infarction - Pipeline by Targazyme, Inc., H2 2014 78
Myocardial Infarction - Pipeline by Aprogen, Inc., H2 2014 79
Myocardial Infarction - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2014 80
Myocardial Infarction - Pipeline by APT Therapeutics, Inc., H2 2014 81
Myocardial Infarction - Pipeline by DecImmune Therapeutics, Inc., H2 2014 82
Myocardial Infarction - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 83
Myocardial Infarction - Pipeline by Immune Pharmaceuticals, Inc., H2 2014 84
Myocardial Infarction - Pipeline by CellProthera SAS, H2 2014 85
Myocardial Infarction - Pipeline by Recardio GmbH, H2 2014 86
Myocardial Infarction - Pipeline by BEAT BioTherapeutics Corp., H2 2014 87
Assessment by Monotherapy Products, H2 2014 88
Assessment by Combination Products, H2 2014 89
Number of Products by Stage and Target, H2 2014 92
Number of Products by Stage and Mechanism of Action, H2 2014 96
Number of Products by Stage and Route of Administration, H2 2014 99
Number of Products by Stage and Molecule Type, H2 2014 102
Myocardial Infarction Therapeutics - Recent Pipeline Updates, H2 2014 239
Myocardial Infarction - Dormant Projects, H2 2014 305
Myocardial Infarction - Discontinued Products, H2 2014 307

List of Figures
Number of Products under Development for Myocardial Infarction, H2 2014 18
Number of Products under Development for Myocardial Infarction - Comparative Analysis, H2 2014 19
Number of Products under Development by Companies, H2 2014 20
Number of Products under Investigation by Universities/Institutes, H2 2014 25
Comparative Analysis by Late Stage Development, H2 2014 27
Comparative Analysis by Clinical Stage Development, H2 2014 28
Comparative Analysis by Early Stage Products, H2 2014 29
Assessment by Monotherapy Products, H2 2014 88
Number of Products by Top 10 Target, H2 2014 90
Number of Products by Stage and Top 10 Target, H2 2014 91
Number of Products by Top 10 Mechanism of Action, H2 2014 94
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 95
Number of Products by Top 10 Route of Administration, H2 2014 98
Number of Products by Stage and Top 10 Route of Administration, H2 2014 99
Number of Products by Top 10 Molecule Type, H2 2014 100
Number of Products by Stage and Top 10 Molecule Type, H2 2014 101

【掲載企業】

Sanofi
AstraZeneca PLC
Advanced Cell Technology, Inc.
Athersys, Inc.
GlaxoSmithKline plc
Merck & Co., Inc.
BioLineRx, Ltd.
FibroGen, Inc.
Laboratoires Pierre Fabre SA
Zydus Cadila Healthcare Limited
Hadasit Medical Research Services & Development Ltd
A. Menarini Industrie Farmaceutiche Riunite Srl
Bayer AG
Merck KGaA
Ligand Pharmaceuticals, Inc.
Lixte Biotechnology Holdings, Inc.
Mesoblast Limited
Compugen Ltd.
Cardio3 BioSciences SA
CSL Limited
NeoStem, Inc.
LG Life Sciences, Ltd.
Pluristem Therapeutics Inc.
Juventas Therapeutics, Inc.
Bharat Biotech International Limited
Omni Bio Pharmaceutical Inc.
Remedy Pharmaceuticals, Inc.
Fina Biotech
QUANTUM GENOMICS Corp.
Angion Biomedica Corp.
GliaMed, Inc.
TaiGen Biotechnology Co., Ltd.
Lacer, S.A.
ViroMed Co., Ltd.
Medestea Research & Production S.p.A.
Lee's Pharmaceutical Holdings Limited
Genextra S.p.a.
Vicore Pharma AB
Cellmid Limited
Saneron CCEL Therapeutics, Inc.
Serodus ASA
Targazyme, Inc.
Aprogen, Inc.
Amarantus Bioscience Holdings, Inc.
APT Therapeutics, Inc.
DecImmune Therapeutics, Inc.
Inbiopro Solutions Pvt. Ltd.
Immune Pharmaceuticals, Inc.
CellProthera SAS
Recardio GmbH
BEAT BioTherapeutics Corp.

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[心筋梗塞:治療薬開発パイプライン動向(2014年下半期)]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月10日現在 219,328 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆